Search

Search Constraints

You searched for: Author/Creator Valent, Jason

Search Results

3. Progression with clinical features is associated with worse subsequent survival in multiple myeloma. Issue 4 (6th February 2019)

4. Health‐related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: Results from the ANDROMEDA study. Issue 6 (30th March 2022)

6. Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma. Issue 3 (11th March 2020)

7. Evidence-based recommendations for induction and maintenance treatment of newly diagnosed transplant-ineligible multiple myeloma patients. (August 2022)

8. Characterisation and prognostic impact of immunoparesis in relapsed multiple myeloma. (28th February 2020)

9. Real‐world data on safety and efficacy of venetoclax‐based regimens in relapsed/refractory t(11;14) multiple myeloma. (3rd February 2020)

10. Validation of the IMPEDE VTE score for prediction of venous thromboembolism in multiple myeloma: a retrospective cohort study. (17th May 2021)